Clinical Commander

Back to dossier
cardio.cardiogenic-shock.septic-mixed.v1PRODUCTION
cardio.cardiogenic-shock.septic-mixed.v1

Cardiogenic shock — septic-mixed (SICM + distributive overlap)

cardiologyacuteadult
Hard-required inputs
0 / 9
Care setting:

Encounter flow

11/12 authored

Canonical 12-phase frame with authored status for this dossier.

Current phase

Frame

Detailed

Mixed septic + cardiogenic shock = sepsis source actively driving distributive collapse PLUS sepsis-induced cardiomyopathy or pre-existing LV dysfunction unmasked. Run BOTH bundles in parallel: SSC 2021 (cultures + abx <60min + lactate + 30 mL/kg + NE) AND CS bundle (echo + inotrope add-on if low CI + cautious volume).

Inputs
2
Actions
0
Advance rule
Set
Advance when

Mixed-shock phenotype recognized + dual bundles activated

Patient inputs (9)

Compensatory tachy + arrhythmia screen on inotrope titration

KDIGO AKI staging + drug dosing (milrinone renal-adjust required)

Source identification + control is non-negotiable per SSC 2021 — drives antibiotic spectrum + procedural intervention timing

Type-2 demand mismatch is common in sepsis; helps differentiate primary ACS from SICM/sepsis-driven myocardial injury (4th UDMI 2018)

Central venous saturation — low ScvO2 (<70%) + low MAP confirms low CO state requiring inotrope; distinguishes pure distributive (high ScvO2) from mixed cardiogenic overlap

Serial bedside echo for SICM (global LV dysfunction acute during sepsis), RV function, valvular dysfunction, fluid responsiveness (IVC + LVOT VTI variability)

Exclude primary STEMI / OMI as cause of shock; type-2 ischemia on stress of sepsis common but does not drive cath lab activation

Sustained SBP <90 / MAP <65 on NE drives the shock-trigger threshold per SSC 2021 + SCAI 2022

SCAI 2022 staging + SSC 2021 hour-1 bundle marker; trajectory drives inotrope add-on decision when lactate fails to clear despite NE + adequate MAP

* = hard-required. Engine cannot meaningfully run until these are filled.

Severity triggers (5)

5 need judgement
  • informationallife_threateninglactate_not_clearing_despite_ne_plus_volume
    Lactate not clearing at 2h despite NE titration to MAP ≥65 and adequate volume → cardiogenic component dominant → ADD low-dose dobutamine EARLY, not more NE
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateningmixed_shock_with_uncontrolled_source
    Mixed septic + CS with source NOT controlled within 6–12h (abscess undrained, line not removed, dead bowel) → urgent procedural/surgical intervention
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseveresicm_with_severe_global_lv_dysfunction
    STAT echo during sepsis shows acute global LV dysfunction with EF drop ≥10 points from baseline → SICM phenotype
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseverepersistent_vasopressor_dependence
    NE >0.25 µg/kg/min sustained → add vasopressin + hydrocortisone per SSC 2021 + ADRENAL 2018
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalsevereover_resuscitation_with_pulmonary_edema_in_sicm
    Crystalloid >30 mL/kg given + new pulmonary edema in SICM phenotype → pause fluids, start cautious diuresis once MAP stable
    Trigger could not be auto-evaluated — needs clinician judgement.

Workflow calculators

Run this disease's risk and dosing calculators inline.

RED_FLAGSrequiredDrives risk stratification
Loading…

Recommended regimen

Mixed septic + cardiogenic shock — NE + early inotrope (low-dose dobutamine) + SSC 2021 bundle + source control; AVOID over-vasoconstriction and high-dose inotropes
axis: septic_mixed_cs_phenotype
Selected axis "Mixed septic + cardiogenic shock — NE + early inotrope (low-dose dobutamine) + SSC 2021 bundle + source control; AVOID over-vasoconstriction and high-dose inotropes" by default fallback (first axis)
  • norepinephrine
    first line
    alpha_beta_pressor
    0.05–0.5 µg/kg/min IV titrate to MAP ≥65 • IV • continuous
    triggers: septic_shock_with_persistent_hypotension
    SOAP-II first-line (PMID 20200382); SSC 2021 strong recommendation
    rxcui 7512
  • dobutamine
    first line
    beta1_inotrope
    2.5–5 µg/kg/min IV (low-dose only) • IV • continuous
    triggers: low_ci_or_low_scvo2_despite_adequate_map_and_volume
    EARLY inotrope add-on when MAP target met but lactate / SvO2 indicate low CO from SICM; high-dose causes arrhythmia + ↑ MVO2 (DOREMI PMID 33704937; ACC/AHA 2022 HF Guideline)
    rxcui 3616
  • vasopressin
    second line
    V1_agonist
    0.03 U/min fixed • IV • continuous
    triggers: NE_above_0.25_µg/kg/min
    SSC 2021 + VASST (Russell NEJM 2008 PMID 18305265) — adjunct to NE; pulmonary-vascular sparing
    rxcui 11149
  • hydrocortisone
    second line
    glucocorticoid
    50 mg IV q6h (200 mg/d) • IV • q6h
    triggers: persistent_NE_above_0.25_µg/kg/min, septic_shock_with_relative_adrenal_insufficiency
    ADRENAL 2018 (Venkatesh NEJM 2018 PMID 29347874) — faster shock resolution; APROCCHSS 2018 (Annane NEJM PMID 29490185) — mortality benefit
    rxcui 5492
  • milrinone
    second line
    PDE3_inhibitor
    0.125–0.5 µg/kg/min IV (no bolus, renal adjust) • IV • continuous
    triggers: BB_dependent_with_sicm, pulmonary_HTN, failure_of_dobutamine
    Inodilator; non-inferior to dobutamine in CS (DOREMI PMID 33704937); avoid if SBP <90 (vasodilator effect)
    rxcui 52769
  • vancomycin
    first line
    glycopeptide_antibiotic
    25–30 mg/kg IV load then 15–20 mg/kg q8–12h (renal-adjust by AUC/MIC) • IV • q8–12h
    triggers: septic_shock_empiric_gram_positive_coverage
    SSC 2021 strong recommendation — broad-spectrum within 1 hour of recognition
    rxcui 11124
  • piperacillin-tazobactam
    first line
    betalactam_betalactamase_inhibitor
    4.5 g IV q6h (extended infusion if hemodynamically tolerated) • IV • q6h
    triggers: septic_shock_empiric_gram_negative_coverage
    SSC 2021 — broad gram-negative coverage; consider meropenem if ESBL risk
    rxcui 74169

outpatient playbook — drug actions (1)

  1. 1. discontinue GDMT if SICM fully recovered
    rxcui 1656328
    wean ARNI/BB/MRA if EF normalizes ≥50% on echo at 3 mo • PO • taper per cardiology
    trigger: Full SICM recovery confirmed
    GDMT not indicated if EF fully recovered (TRED-HF PMID 30429038 cautions on full GDMT withdrawal — taper carefully)

Auto-drafted A&P note

outpatient

Subjective

- Possible entry pathways: Septic shock + persistent low CI / low SvO2 despite NE titration + 30 mL/kg crystalloid → mixed CS overlap; Bedside echo during sepsis: new global LV dysfunction with EF drop ≥10 points from baseline (SICM phenotype, often reversible at 7–10d); STAT troponin elevated in septic patient WITHOUT primary ACS pattern on ECG → type-2 demand-mismatch ischemia or SICM.

Objective

- No vitals, labs, or imaging entered for this encounter.

Assessment

**Cardiogenic shock — septic-mixed (SICM + distributive overlap)** (cardio.cardiogenic-shock.septic-mixed.v1).
Scope: Mixed septic + cardiogenic shock = sepsis source actively driving distributive collapse PLUS sepsis-induced cardiomyopathy or pre-existing LV dysfunction unmasked. Run BOTH bundles in parallel: SSC 2021 (cultures + abx <60min + lactate + 30 mL/kg + NE) AND CS bundle (echo + inotrope add-on if low CI + cautious volume).

No severity triggers fired against current inputs.

Plan

Regimen axis: **Mixed septic + cardiogenic shock — NE + early inotrope (low-dose dobutamine) + SSC 2021 bundle + source control; AVOID over-vasoconstriction and high-dose inotropes**.
1. norepinephrine 0.05–0.5 µg/kg/min IV titrate to MAP ≥65 IV continuous (alpha_beta_pressor, first line) — SOAP-II first-line (PMID 20200382); SSC 2021 strong recommendation
2. dobutamine 2.5–5 µg/kg/min IV (low-dose only) IV continuous (beta1_inotrope, first line) — EARLY inotrope add-on when MAP target met but lactate / SvO2 indicate low CO from SICM; high-dose causes arrhythmia + ↑ MVO2 (DOREMI PMID 33704937; ACC/AHA 2022 HF Guideline)
3. vasopressin 0.03 U/min fixed IV continuous (V1_agonist, second line) — SSC 2021 + VASST (Russell NEJM 2008 PMID 18305265) — adjunct to NE; pulmonary-vascular sparing
4. hydrocortisone 50 mg IV q6h (200 mg/d) IV q6h (glucocorticoid, second line) — ADRENAL 2018 (Venkatesh NEJM 2018 PMID 29347874) — faster shock resolution; APROCCHSS 2018 (Annane NEJM PMID 29490185) — mortality benefit
5. milrinone 0.125–0.5 µg/kg/min IV (no bolus, renal adjust) IV continuous (PDE3_inhibitor, second line) — Inodilator; non-inferior to dobutamine in CS (DOREMI PMID 33704937); avoid if SBP <90 (vasodilator effect)
6. vancomycin 25–30 mg/kg IV load then 15–20 mg/kg q8–12h (renal-adjust by AUC/MIC) IV q8–12h (glycopeptide_antibiotic, first line) — SSC 2021 strong recommendation — broad-spectrum within 1 hour of recognition
7. piperacillin-tazobactam 4.5 g IV q6h (extended infusion if hemodynamically tolerated) IV q6h (betalactam_betalactamase_inhibitor, first line) — SSC 2021 — broad gram-negative coverage; consider meropenem if ESBL risk

Setting playbook (outpatient) — Long-term post-sepsis surveillance — confirm full SICM recovery (echo at 3 mo if any residual dysfunction), GDMT maintenance if HFrEF persists, vaccine completion, mental health continuity
8. discontinue GDMT if SICM fully recovered wean ARNI/BB/MRA if EF normalizes ≥50% on echo at 3 mo PO taper per cardiology — Full SICM recovery confirmed (GDMT not indicated if EF fully recovered (TRED-HF PMID 30429038 cautions on full GDMT withdrawal — taper carefully))

Non-pharmacologic actions:
- Mental health follow-up (post-sepsis depression + PTSD common)
- Annual vaccine maintenance

AVOID / contraindication checks:
- Beta_blocker_AVOID_in_acute_cardiogenic_shock_or_sicm (ACC/AHA 2022)
- High_dose_dobutamine_AVOID_arrhythmia_and_increased_MVO2 (DOREMI PMID 33704937)
- Over_resuscitation_AVOID_pulmonary_edema_in_sicm (FENICE registry framework)
- Vasopressin_AVOID_in_pulmonary_HTN_or_severe_RV_failure (V1 worsens PVR)
- Milrinone_AVOID_if_sbp_below_90_vasodilator_effect (DOREMI)
- Nephrotoxic_abx_renal_dose_adjust (CKD EPI 2021)
- Source_control_NON_NEGOTIABLE_per_ssc_2021 (Evans CCM 2021 PMID 34599691)

Monitoring

Regimen monitoring:
- arterial line continuous BP (SSC 2021)
- central venous access with scvo2 (SSC 2021)
- lactate q1 2h until clearing (SSC 2021 + SCAI 2022)
- UOP hourly (SSC 2021 perfusion marker)
- echo at baseline then q24 48h for sicm recovery (typical 7–10d reversibility)
- serial troponin BNP (4th UDMI; HF guidelines)
- cortisol random if persistent pressor dependence (ADRENAL 2018)
- abx de escalation at 48 72h per culture results (SSC 2021)
- source control documentation (SSC 2021)

Setting (outpatient) monitoring:
- Annual visits
- Echo only if symptomatic or residual dysfunction

Follow-up plan: Repeat echo at 7–10d to confirm SICM recovery; if persistent LV dysfunction → GDMT initiation per HFrEF pathway (PIONEER-HF cadence); ICU-acquired weakness rehab; post-sepsis syndrome surveillance
- Close-out criterion: Recovery echo + post-sepsis plan booked

Monitoring phase: A-line + central line + serial lactate q1–2h + ScvO2 + UOP hourly; daily echo for SICM recovery (typical 7–10d); abx de-escalation per SSC 2021; cortisol axis if persistent vasopressor dependence

Disposition

Current setting: outpatient — Long-term post-sepsis surveillance — confirm full SICM recovery (echo at 3 mo if any residual dysfunction), GDMT maintenance if HFrEF persists, vaccine completion, mental health continuity

Disposition criteria:
- Long-term continuation; cross-link to cardio.hf.core.v1 if HFrEF persists

Escalation triggers (move to higher acuity):
- Recurrent sepsis → urgent ED + sepsis pathway
- New HF symptoms → echo + GDMT re-initiation

Earlier-Return Triggers

Return-precaution thresholds (watch for):
- [LIFE_THREATENING] Lactate not clearing at 2h despite NE titration to MAP ≥65 and adequate volume → cardiogenic component dominant → ADD low-dose dobutamine EARLY, not more NE
- [LIFE_THREATENING] Mixed septic + CS with source NOT controlled within 6–12h (abscess undrained, line not removed, dead bowel) → urgent procedural/surgical intervention
- [SEVERE] STAT echo during sepsis shows acute global LV dysfunction with EF drop ≥10 points from baseline → SICM phenotype

Citations

- Surviving Sepsis Campaign 2021 (Evans CCM 2021, PMID 34599691) + SCAI Cardiogenic Shock Classification 2022 (Naidu JACC 2022, PMID 35718438) + 2022 AHA/ACC/HFSA HF Guideline (Heidenreich Circulation 2022, PMID 35363499) + Sepsis-3 (Singer JAMA 2016) [PMID:34599691](https://pubmed.ncbi.nlm.nih.gov/34599691/)
- Cited evidence (PMID 26903337) [PMID:26903337](https://pubmed.ncbi.nlm.nih.gov/26903337/)
- Cited evidence (PMID 35718438) [PMID:35718438](https://pubmed.ncbi.nlm.nih.gov/35718438/)
- Cited evidence (PMID 20200382) [PMID:20200382](https://pubmed.ncbi.nlm.nih.gov/20200382/)
- Cited evidence (PMID 33704937) [PMID:33704937](https://pubmed.ncbi.nlm.nih.gov/33704937/)

Last reconciled with current guidelines: 2026-05-14.
References
  • Surviving Sepsis Campaign 2021 (Evans CCM 2021, PMID 34599691) + SCAI Cardiogenic Shock Classification 2022 (Naidu JACC 2022, PMID 35718438) + 2022 AHA/ACC/HFSA HF Guideline (Heidenreich Circulation 2022, PMID 35363499) + Sepsis-3 (Singer JAMA 2016) — PMID:34599691
  • Cited evidence (PMID 26903337) — PMID:26903337
  • Cited evidence (PMID 35718438) — PMID:35718438
  • Cited evidence (PMID 20200382) — PMID:20200382
  • Cited evidence (PMID 33704937) — PMID:33704937